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Background: Significant variability of phenotype and age of onset are well known in TTR-FAP 
associated to a wide spectrum of pathogenic TTR variants, among which Val30Met is the most 
frequent [1,2]. Recently, new therapeutic options became available in TTR-FAP that should be 
administered from the very onset of symptoms. In this context, the knowledge of the risk of being 
symptomatic for mutation carriers (penetrance) is essential to adjust the follow-up of carriers and 
for patient management [3,4]. This study aims to refine penetrance estimates in the main pathogenic 
TTR variants encountered in our TTR-FAP population using a newly developed non parametric 
approach named NPSE for Non-Parametric Survival Estimate. 
Materials and methods: A systematic genealogical enquiry was carried out in each family 
assessed in our center. Relevant data were collected with special attention to the genotype, 
phenotype, age at onset (AO) for affected individuals and age at last news for asymptomatic carriers 
and relatives. Portuguese families were not included in this study. 
In previous works, we estimated penetrance as function of age, using a parametric survival method 
the PEL (Proband’s Exclusion Likelihood) [6] in which the AO is modeled by a Weibull 
distribution (WD). However, such method does not fit properly when penetrance function is far 
from WD. To avoid this bias, we have developed a non-parametric approach NPSE [5] based on a 
survival analysis (Kaplan-Meier estimator) that fits any penetrance shape. Also, NPSE can take into 
account covariates, here the TTR variant, through a Cox Model.  
Results: We obtained genealogical data from 71 unrelated kindreds, including Val30Met (35 
families, 90 patients), Ser77Tyr (15 families, 47 patients), Ile107Val (12 families, 21 patients), 
Ser77Phe (9 families, 30 patients) with information on 1654 subjects (188 affected /115 
asymptomatic carriers).  
Mean age at onset (± Standard Deviation ) was 54.6 years (± 14.9) for Val30Met, 55.6 years (± 9.1) 
for Ser77Tyr, 58.7 years (± 6.4) for Ser77Phe and 62.3 years (± 6.8) for Ile107Val. 
Penetrance estimates were significantly different between the 4 TTR variants tested (p= 0.003) and 
remained incomplete in elderly. Hence, at 80 years of age, penetrance (95% Confidence Interval) 
varies from 46.9%, (16.6-66.2) in Ile107Val up to 71.3% (51.1-83.1) for Ser77Tyr kindred.  
The disease risk is virtually null up to the age of 50 years for all variants except in the Val30Met 
group where it increases progressively from 3.1% (95% CI, 0.3-5.7) at 30 years to 16.5% (9.8-22.7) 
at 50 and 64.4% (49.4-74.9) at 80 years old. In contrast, in non Val30Met variants, the risk 
increased abruptly after 50 years old. In Ser77Phe and Ser77Tyr carriers, it raised from 7% (0.8-
15.8) and 12.8% (3.3- 21.4) respectively up to 65.8% (37.1-81.4) and 71.3% (51.1-83.1). Risk 
estimate was found the lowest in Ile107Val families where it increases progressively from 50 years 
to 37.5% (14.2-54.4) at 70 y-o. 
 
Discussion and Conclusions: This study showed significant differences of penetrance profiles in 
TTR-FAP with various pathogenic mutations of TTR. Our results should be replicated and 
implemented on larger samples of families to refine the management of carriers. NPSE method is 
more accurate and powerful than PEL previously used to unravel penetrance estimates. In future 
studies, it will allow testing the effect of other covariates, like gender, origin, and parent of origin 
on disease expression.  
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